<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Additional ", fill: "#f5fffa"},
{source: "3: Additional ", target: "3: uncertainties", fill: "#f5fffa"},
{source: "3: uncertainties", target: "3: immaterial may also impair", fill: "#f5fffa"},
{source: "3: immaterial may also impair", target: "3: financial condition", fill: "#f5fffa"},
{source: "3: financial condition", target: "3: operations", fill: "#f5fffa"},
{source: "3: Additional ", target: "14: future capital requirements will depend on", fill: "#f4f0ec"},
{source: "14: future capital requirements will depend on", target: "14: continued scientific", fill: "#f4f0ec"},
{source: "14: continued scientific", target: "14: development", fill: "#f4f0ec"},
{source: "14: development", target: "14: complexity", fill: "#f4f0ec"},
{source: "14: complexity", target: "14: development programs", fill: "#f4f0ec"},
{source: "14: development programs", target: "14: regulatory approvals", fill: "#f4f0ec"},
{source: "14: regulatory approvals", target: "14: Contents ", fill: "#f4f0ec"},
{source: "14: Contents ", target: "14: technological", fill: "#f4f0ec"},
{source: "14: technological", target: "14: developments", fill: "#f4f0ec"},
{source: "14: developments", target: "14: collaborative", fill: "#f4f0ec"},
{source: "14: collaborative", target: "14: arrangements", fill: "#f4f0ec"},
{source: "14: arrangements", target: "14: manufacturing", fill: "#f4f0ec"},
{source: "14: manufacturing", target: "14: commercialization", fill: "#f4f0ec"},
{source: "14: commercialization", target: "14: effective", fill: "#f4f0ec"},
{source: "14: future capital requirements will depend on", target: "68: United States ", fill: "#d19fe8"},
{source: "68: United States ", target: "122: distributor", fill: "#98ff98"},
{source: "122: distributor", target: "122: distributors", fill: "#98ff98"},
{source: "122: distributors", target: "122: timely basis", fill: "#98ff98"},
{source: "122: timely basis", target: "122: on terms which", fill: "#98ff98"},
{source: "122: on terms which", target: "122: commercially reasonable", fill: "#98ff98"},
{source: "122: commercially reasonable", target: "122: present relationships", fill: "#98ff98"},
{source: "122: distributor", target: "START_HERE", fill: "#98ff98"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Met_Operations">Met Operations</a></td>
      <td>Met Operations, also known as Met Ops, is one of the four business groups which forms the Metropolitan Police Service. It was created during the 2018-19 restructuring of the service, amalgamating many of its functions from the Operations side of the Specialist Crime &amp; Operations Directorate formed in 2012, with the Specialist Crime side of that Directorate placed under the new Frontline Policing Directorate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/History_of_the_United_States">History of the United States</a></td>
      <td>The history of the lands that became the United States began with the arrival of the first people in the Americas around 15,000 BC. Numerous indigenous cultures formed, and many saw transformations in the 16th century away from more densely populated lifestyles and towards reorganized polities elsewhere.  The European colonization of the Americas began in the late 15th century, however most colonies in what would later become the United States were settled after 1600.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Foodservice_distributor">Foodservice distributor</a></td>
      <td>A food service distributor is a company that provides food and non-food products to restaurants, cafeterias, industrial caterers, hospitals, schools/colleges/universities, nursing homes, and anywhere food is served away from the home.\n\n\n== Description ==\nA food service distributor functions as an intermediary between food manufacturers and the food service operator (usually a chef, food service director, food and beverage manager, and independent food preparation businesses operator owners.)  The distributor purchases, stores, sells, and delivers those products, providing food service operators with access to items from a wide variety of manufacturers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Brewers'_Distributor">Brewers' Distributor</a></td>
      <td>Brewers' Distributor Ltd. (BDL) is a Canadian company that distributes beer throughout the four western provinces and three northern territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hartford_Distributors_shooting">Hartford Distributors shooting</a></td>
      <td>The Hartford Distributors shooting was a mass shooting that occurred on August 3, 2010, in Manchester, Connecticut, United States. The location of the crime was a warehouse owned by Hartford Distributors, a beer distribution company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Quality_Distributors">Quality Distributors</a></td>
      <td>Quality Distributors FC are a professional association football (soccer) club in Guam. They play in the Guam Soccer League.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/General_Film_Distributors">General Film Distributors</a></td>
      <td>General Film Distributors (GFD), later known as J. Arthur Rank Film Distributors and Rank Film Distributors Ltd., was a British film distribution company based in London. It was active between 1935 and 1996, and from 1937 it was part of the Rank Organisation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Titan_Distributors">Titan Distributors</a></td>
      <td>Titan Distributors was a British comic book distributor which existed from 1978 to 1993, when it was acquired by a larger U.S. distributor. Operated by Nick Landau, Mike Lake, and Mike Luckman, Titan Distributors supplied comics, science fiction, and other genre products to retailers all over the United Kingdom.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sony_Pictures_Motion_Picture_Group">Sony Pictures Motion Picture Group</a></td>
      <td>Sony Pictures Entertainment Motion Picture Group (commonly known as Sony Pictures Motion Picture Group, formerly known as the Columbia TriStar Motion Picture Group until 2013, and abbreviated as SPMPG) is a division of Sony Pictures Entertainment to manage its motion picture operations. It was launched in 1998 by integrating the businesses of Columbia Pictures Industries, Inc.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>EP MEDSYSTEMS INC      Item 1A Risk Factors        In addition to the other information set forth in this annual report, you     <font color="blue">should carefully</font> consider the <font color="blue">following factors</font> that <font color="blue"><font color="blue">could materially</font> affect</font>     our  business,  financial  condition  or future results</td>
    </tr>
    <tr>
      <td>The risks and     <font color="blue">uncertainties</font> described below are not the only risks and <font color="blue">uncertainties</font> that     we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not currently known to us or     that  we currently deem to be <font color="blue">immaterial may also impair</font> our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  were incorporated in January 1993 and completed the <font color="blue">initial public</font>     offering of our <font color="blue">common stock</font> in June 1996</td>
    </tr>
    <tr>
      <td>We have incurred substantial     operating losses in <font color="blue">each year since</font> our <font color="blue">incorporation</font></td>
    </tr>
    <tr>
      <td><font color="blue">At <font color="blue">December </font></font>31, 2005, we had an <font color="blue">accumulated deficit</font> of approximately dlra48dtta3     million</td>
    </tr>
    <tr>
      <td>Our <font color="blue">net sales revenue</font> of dlra16dtta7 million, less cost of sales, did not     cover our operating expenses of approximately dlra16dtta2 million for the year     ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td><font color="blue">At <font color="blue">December </font></font>31, 2004, we had an <font color="blue">accumulated deficit</font>     of approximately dlra42dtta6 million</td>
    </tr>
    <tr>
      <td>Our <font color="blue">net sales revenue</font> of dlra16dtta4 million, less     cost of sales, did not cover our operating expenses of approximately dlra13dtta9     million for the year ended <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>We expect that our operating     <font color="blue">expenses <font color="blue">will continue</font></font> to exceed our revenues, and as such, we <font color="blue">will likely</font>     continue to incur operating <font color="blue">losses unless</font> and <font color="blue">until <font color="blue">revenue from</font> newer</font>     <font color="blue">products covers</font> our costs</td>
    </tr>
    <tr>
      <td>We may need <font color="blue"><font color="blue">additional</font> funds</font> to support our <font color="blue">operations</font> and we may need to     reduce our <font color="blue">operations</font>, sell stock or assets, or <font color="blue">merge with</font> another entity to     continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> to date have consumed substantial capital resources, and we     <font color="blue">will continue</font> to expend substantial and <font color="blue">increasing amounts</font> of capital for     research, product <font color="blue">development</font> and testing to establish commercial-scale     <font color="blue"><font color="blue">manufacturing</font> cap<font color="blue">abilities</font></font>, and to <font color="blue">market potential</font> and <font color="blue">approved products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">future capital requirements</font> will depend on</font> many factors, including:           •   <font color="blue">continued scientific</font> progress in our research and <font color="blue">development</font>     programs;           •   the size and <font color="blue">complexity</font> of our research and <font color="blue">development</font> programs;           •   the scope and results of testing and trials of our products;           •   the time and costs involved in applying for <font color="blue"><font color="blue">regulatory approval</font>s</font>;                                           13     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>  •   the costs involved in preparing, filing, prosecuting, maintaining and     enforcing patent claims;           •   competing <font color="blue">technological</font> and market <font color="blue">development</font>s;           •   our ability to establish and maintain <font color="blue">collaborative</font> research and     <font color="blue">development</font> <font color="blue"><font color="blue">arrangement</font>s</font>;           •   the cost of <font color="blue">manufacturing</font> scale-up and product <font color="blue">commercialization</font>;           •   our ability to create an <font color="blue">effective</font> sales channel for our products; and           •   the costs of being a public company</td>
    </tr>
    <tr>
      <td>We may need to raise <font color="blue"><font color="blue">additional</font> funds</font> in order to satisfy these and other     <font color="blue">future capital requirements</font></td>
    </tr>
    <tr>
      <td>If we are not able to do so, we may not be able     to  fund  our  future  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We expect that our existing capital     resources, including the <font color="blue">capital previously raised through</font> the sale of     common  stock and the issuance of convertible notes under our existing     revolving credit <font color="blue">facility</font>, will be sufficient to fund our <font color="blue"><font color="blue">activities</font> as</font>     currently planned through the end of the <font color="blue">first quarter</font> of 2007</td>
    </tr>
    <tr>
      <td>However, in     the event our sales do not meet budgeted amounts, our capital <font color="blue">expenditures</font>     increase over our estimates, we are unable to convert our outstanding notes     into shares of our <font color="blue">common stock</font> and/or we are unable to borrow <font color="blue">additional</font>     funds under our existing revolving credit <font color="blue">facility</font>, it is likely that we     will  need <font color="blue">additional</font> financing sooner than currently expected</td>
    </tr>
    <tr>
      <td>In the     future, it is possible that we will not have adequate resources to support     our business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We may seek <font color="blue">additional</font> funding, including public and <font color="blue">private financings</font></td>
    </tr>
    <tr>
      <td>Our     choice of <font color="blue">financing <font color="blue">alternative</font>s may vary from</font> time to time <font color="blue">depending upon</font>     <font color="blue">various factors</font>, including the <font color="blue">market price</font> of our securities, conditions in     the <font color="blue">financial markets</font>, and the interest of other entities in strategic     <font color="blue"><font color="blue">transactions</font> with us</font></td>
    </tr>
    <tr>
      <td>There can be no guarantee that <font color="blue">additional</font> financing     will  be  available  on  acceptable terms, whether through borrowings,     <font color="blue">collaborative</font> <font color="blue">arrangement</font>, issuance of securities, or otherwise</td>
    </tr>
    <tr>
      <td>If adequate     funds  are  not  available, we may be required to delay, scale back or     <font color="blue">eliminate one</font> or more of our research and <font color="blue">development</font> programs or other     <font color="blue">initiatives</font></td>
    </tr>
    <tr>
      <td>We may also need to obtain funds through <font color="blue"><font color="blue">arrangement</font>s</font> with     <font color="blue">collaborative</font> partners or others that require us to <font color="blue">relinquish rights</font> to     <font color="blue">certain <font color="blue">technologies</font></font> or <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Any such delay, scale back,     <font color="blue">partnership</font> or similar <font color="blue"><font color="blue">arrangement</font> could</font> have a <font color="blue">negative <font color="blue">impact on</font></font> our     ability to develop products, or to achieve <font color="blue">profitability</font> if our products are     brought  to  market</td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> financing is not available to us on     acceptable terms, or at all, it would have a material adverse effect on our     business, <font color="blue">financial condition</font>, prospects and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may need to establish <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font>, and this could have a     negative effect on our freedom to operate our business, <font color="blue">fund new product</font>     <font color="blue">development</font> or <font color="blue"><font color="blue">profit fully from</font> sales</font> of our products</td>
    </tr>
    <tr>
      <td>We may seek to <font color="blue">collaborate with</font> other medical device companies to gain     access  to  their  research and <font color="blue">development</font>, <font color="blue">manufacturing</font>, marketing,     <font color="blue">distribution cap<font color="blue">abilities</font></font> and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>However, we may not be     able to negotiate <font color="blue"><font color="blue">arrangement</font>s</font> with any <font color="blue">collaborative</font> partners on acceptable     terms</td>
    </tr>
    <tr>
      <td>Any <font color="blue">collaborative</font> relationships that we <font color="blue">enter into may</font> include     <font color="blue"><font color="blue">restrictions</font> on</font> our freedom to operate our business or to <font color="blue">profit fully from</font>     the sales of our products</td>
    </tr>
    <tr>
      <td>Once a <font color="blue">collaborative</font> <font color="blue">arrangement</font> is established, our partner may <font color="blue">discontinue</font>     its funding of any <font color="blue">particular program</font> or may, either alone or <font color="blue">with others</font>,     <font color="blue">pursue <font color="blue">alternative</font> <font color="blue">technologies</font></font> for the <font color="blue">medical conditions</font> our products are     intended to treat</td>
    </tr>
    <tr>
      <td>If a partner were to develop, or to establish an economic     interest in, a competing product, such partner may withdraw financial or     <font color="blue">technological</font> resources from the <font color="blue">development</font> of our <font color="blue">collaborative</font> product or     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Without  </font><font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font>, we must fund our own research and     <font color="blue">development</font>  <font color="blue">activities</font>, accelerating the depletion of our capital and     requiring us to develop our own <font color="blue">marketing cap<font color="blue">abilities</font></font></td>
    </tr>
    <tr>
      <td>Therefore, if we are     unable to establish and maintain <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> on acceptable     terms, we could experience a material adverse effect on our ability to     develop products and, once developed, to <font color="blue">market them <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>Our  success  will  depend  on  continued  market  <font color="blue">acceptance</font>  of  the     EP-WorkMate^^®^ and market <font color="blue">acceptance</font> of our EP-WorkMate^^®^ <font color="blue">integrated with</font>     RPM™, the EP-4™ Stimulator, the ALERT^^®^ System and ViewMate^^®^ and other     <font color="blue">product offerings</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue"><font color="blue">increase revenues</font> over</font> the <font color="blue">next several years will depend on</font>     the   continued  market  <font color="blue">acceptance</font>  by  <font color="blue">electrophysiologists</font>  of  our     EP-WorkMate^^®^ <font color="blue">computerized monitoring</font> and <font color="blue">analysis workstation integrated</font>     with RPM™, and market <font color="blue">acceptance</font> of our ALERT^^®^ System and ViewMate^^®^     <font color="blue">product offerings</font></td>
    </tr>
    <tr>
      <td>Sales of our EP-WorkMate^^®^,                                           14     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font>its integrated EP-4™ stimulator, and Boston Scientific Corporation’s RPM™     RealTime Position Management™ <font color="blue">system accounted</font> for 85prca, 89prca, and 86prca of our     sales in the year ended <font color="blue">December </font>31, 2005, 2004, and 2003, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Because the EP-WorkMate^^®^ has a list price of approximately dlra175cmam000 with     an integrated EP-4™ Stimulator, each sale of an EP-WorkMate^^®^ <font color="blue">represents</font> a     <font color="blue">relatively</font> large percentage of our net sales</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>and use of our products by physicians and other <font color="blue">clinicians</font> is     critical to our success</td>
    </tr>
    <tr>
      <td>Physician and clinician <font color="blue">acceptance</font> will depend     upon,  among  other things, substantial favorable clinical experience,     <font color="blue">advantages</font> over <font color="blue">alternative</font> <font color="blue">treatments</font>, cost <font color="blue">effective</font>ness and favorable     <font color="blue">reimbursement</font> policies of third-party payors, such as insurance companies,     Medicare and other <font color="blue"><font color="blue">government</font>al programs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Decreased </font>or flat sales or low     market <font color="blue">acceptance</font> of our EP-WorkMate^^®^ products or low market <font color="blue">acceptance</font>     of our recently <font color="blue">approved products</font> could have a material adverse effect on     our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We  are  primarily  engaged in the sale of capital equipment, which is     sensitive to <font color="blue">fluctuations</font> in our customers’ budgets</td>
    </tr>
    <tr>
      <td>We are primarily engaged in the sale of capital goods and, as a result, are     subject to the <font color="blue">budgetary cycles</font> of our customers</td>
    </tr>
    <tr>
      <td>These cycles can cause     <font color="blue">fluctuations</font> in our <font color="blue">quarterly revenue as</font> our <font color="blue">customers manage</font> their capital     <font color="blue">budgets based on available cash</font> to pay for equipment</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">manufacturing</font> experience and <font color="blue">manufacturing</font> capacity, which     may affect our ability to produce <font color="blue">commercially viable products <font color="blue">economically</font></font>     and in <font color="blue">sufficient quantities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">profitability</font> will depend on our ability to <font color="blue">manufacture</font> our products     <font color="blue">efficiently</font> and <font color="blue">economically</font></td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">manufacturing</font> experience,     <font color="blue"><font color="blue">particularly</font> with respect</font> to our <font color="blue">catheter products</font></td>
    </tr>
    <tr>
      <td>Our failure to obtain     <font color="blue">efficiency</font> in our <font color="blue">manufacturing</font> processes will affect our <font color="blue">profitability</font> and     could have a material adverse effect on our business, results of <font color="blue">operations</font>     and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We have limited experience in <font color="blue">manufacturing</font> any of our products in volumes     <font color="blue">necessary</font> for us to achieve commercial <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We may not be able to     establish or maintain reliable, high-volume, cost-<font color="blue">effective</font> <font color="blue">manufacturing</font>     capacity, which is critical to our future <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We  cannot  assure  you  that we will be able to maintain or establish     outsourcing <font color="blue"><font color="blue">arrangement</font>s</font> on acceptable terms</td>
    </tr>
    <tr>
      <td>We <font color="blue">also <font color="blue">cannot assure</font></font> you that     we  will  be  able to <font color="blue">successfully</font> <font color="blue">manufacture</font> our products in volumes     sufficient for us to be profitable or that we can <font color="blue"><font color="blue">successfully</font> increase</font> our     <font color="blue">manufacturing</font> capacity</td>
    </tr>
    <tr>
      <td>We depend on third-party sources to <font color="blue">manufacture</font> certain of our products and     <font color="blue">critical components</font> for our products</td>
    </tr>
    <tr>
      <td>We rely on third-party sources to <font color="blue">manufacture</font> <font color="blue">critical components</font> for the     EP-4™  Stimulators, ViewMate^^®^ and its ViewFlex™ catheter, ALERT^^®^     Companion, EP-WorkMate^^®^ and RPM™ Navigation System</td>
    </tr>
    <tr>
      <td>Any <font color="blue">interruption</font> by                                           15     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>these third-party sources in the supply of <font color="blue">such products</font> or <font color="blue">components would</font>     have a material adverse effect on our ability to deliver those products or     the  products  in  <font color="blue">which such components</font> are used and <font color="blue">could materially</font>     <font color="blue">adversely impact</font> our sales and gross margins</td>
    </tr>
    <tr>
      <td>If any <font color="blue">interruption</font> were to     occur,  we  may not be able to reach an acceptable <font color="blue">arrangement</font> with an     <font color="blue">alternative</font> source of supply on a <font color="blue">timely basis</font> or on acceptable terms</td>
    </tr>
    <tr>
      <td>Our     failure to find <font color="blue">alternative</font> <font color="blue">manufacturing</font> sources could have a material     adverse  effect  on  our business, results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>During the <font color="blue">first quarter</font> of 2006, we discovered non-conforming     material from a supplier of a critical component for our ViewFlex™ catheter</td>
    </tr>
    <tr>
      <td>We expect to resolve this issue in the <font color="blue">second quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on our ability to keep pace with <font color="blue">technological</font>     <font color="blue">development</font>s and marketplace changes</td>
    </tr>
    <tr>
      <td>The  <font color="blue">electrophysiology</font>  market  is  <font color="blue">characterized</font>  by rapidly changing     <font color="blue">technology</font>, <font color="blue">new products</font> and <font color="blue">dynamic industry standards</font></td>
    </tr>
    <tr>
      <td>Accordingly, our     ability  to <font color="blue">compete depends on</font> our ability to develop <font color="blue">new products</font> and     <font color="blue">improve existing products</font> to keep pace with <font color="blue">technological</font> and marketplace     changes</td>
    </tr>
    <tr>
      <td>The research and <font color="blue">development</font> <font color="blue">necessary</font> for <font color="blue">new products</font> and for     <font color="blue">product <font color="blue">refinements</font></font> can take longer and require greater <font color="blue">expenditures</font> than we     expect, and our <font color="blue">efforts may</font> not be successful</td>
    </tr>
    <tr>
      <td>Moreover, any <font color="blue">new products</font> or     <font color="blue">refinements</font>  to existing products may not be accepted by physicians or     patients</td>
    </tr>
    <tr>
      <td>If  we  are unable to <font color="blue">successfully</font> respond to <font color="blue">technological</font>     <font color="blue">development</font>s  or  changes  in the marketplace in which we compete, our     business, <font color="blue">financial condition</font> and <font color="blue">prospects may</font> be <font color="blue">materially adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Our patents and <font color="blue"><font color="blue">proprietary</font> rights might</font> not <font color="blue">provide sufficient intellectual</font>     <font color="blue">property protection</font> for our products</td>
    </tr>
    <tr>
      <td>Our success and ability to compete <font color="blue">effective</font>ly in the <font color="blue">electrophysiology</font>     <font color="blue">marketplace depends on</font> our ability to protect our patents, <font color="blue">proprietary</font>     <font color="blue">technology</font> and other <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>We have acquired, and will seek     to acquire, patents in the <font color="blue"><font color="blue">United States</font> </font>and certain foreign countries</td>
    </tr>
    <tr>
      <td>We     also have <font color="blue">entered into license <font color="blue"><font color="blue">agreement</font>s</font></font> to obtain rights, including patent     rights, of <font color="blue">third parties</font> that we consider important to our business</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that <font color="blue">patents will</font> be issued on our <font color="blue">patent <font color="blue">applications</font></font> and     <font color="blue">applications</font> for which we have acquired licenses</td>
    </tr>
    <tr>
      <td>Further, if pending or     <font color="blue">future patents</font> are issued, they may not be sufficient to <font color="blue">provide us with</font>     <font color="blue">meaningful protection</font> or a <font color="blue">commercial advantage</font></td>
    </tr>
    <tr>
      <td>Additionally, patents we     hold  or  may  hold  in  the  <font color="blue">future may</font> be challenged, invalidated or     <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Moreover, our <font color="blue">competitors</font>, many of whom have substantial     resources and have made substantial investments in <font color="blue">competing <font color="blue">technologies</font></font>,     <font color="blue">may presently</font> have or <font color="blue">may seek patents</font> that will prevent, limit or interfere     with our ability to make, use or sell our products in the <font color="blue"><font color="blue">United States</font> </font>and     other countries</td>
    </tr>
    <tr>
      <td>In  addition  to  patents,  we rely on a <font color="blue">combination</font> of <font color="blue">trade secrets</font>,     <font color="blue">copyrights</font> and <font color="blue">trademarks</font> to protect our <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>For     example,  our  software  (which  is  an  integrated  component  in the     EP-WorkMate^^®^ and EP-4™ Stimulator) is copyrighted; however, existing     copyright   laws   offer   only   limited  practical  protection  from     <font color="blue">misappropriation</font></td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">competitors</font> may <font color="blue">in<font color="blue">dependent</font>ly</font> develop     <font color="blue">substantially</font> equivalent <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">pay royalties</font>, we may lose our rights to use certain     important <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We have entered into several <font color="blue">technology</font> and <font color="blue">licensing <font color="blue"><font color="blue">agreement</font>s</font> which</font>     require  us to <font color="blue">pay royalties</font>, including, in some cases, minimum annual     royalties</td>
    </tr>
    <tr>
      <td>If we do not pay these royalties, we may be in breach of our     <font color="blue">technology</font> <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue">could lose</font> the <font color="blue">rights granted</font> to us under these     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>The loss of these <font color="blue">rights would affect</font> our ability to make,     market and sell the ALERT^^®^ <font color="blue">product line</font> and the RPM™ <font color="blue">product line</font>, which     could have a material <font color="blue">adverse affect on</font> our business, results of <font color="blue">operations</font>,     <font color="blue">financial condition</font> and prospects</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property <font color="blue">litigation</font> could harm</font> our business</td>
    </tr>
    <tr>
      <td>We operate in an industry that is susceptible to <font color="blue"><font color="blue">significant</font> patent</font> and     <font color="blue">intellectual property</font> <font color="blue">litigation</font> and, in <font color="blue">recent years</font>, it has <font color="blue">been common</font>     for companies in the medical device field to <font color="blue">aggressively challenge</font> the     rights of other companies to prevent the marketing of new devices</td>
    </tr>
    <tr>
      <td>We may     have to <font color="blue">defend against</font> third party <font color="blue">intellectual property</font> claims or initiate     <font color="blue">litigation</font> against <font color="blue">third parties</font> that are <font color="blue">infringing on</font> our patents or other     <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>The result of <font color="blue">such <font color="blue">litigation</font> could</font> cause us     to cancel or <font color="blue">delay shipments</font> of any <font color="blue">products found</font> to be employing another     party’s <font color="blue">intellectual property</font> rights, require us to develop <font color="blue">alternative</font>     <font color="blue">technology</font>  or  require  us  to <font color="blue">enter into costly royalty</font> or licensing     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Further, if <font color="blue">necessary</font> licenses are not available to us on     satisfactory terms, we may not be able to redesign our products or processes     to avoid any alleged <font color="blue">infringement</font> of a third party’s <font color="blue">intellectual property</font>     rights</td>
    </tr>
    <tr>
      <td>Accordingly, we could be prevented from <font color="blue">manufacturing</font> and selling     some of our products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font>, with or <font color="blue">without merit</font>, to <font color="blue"><font color="blue">defend against</font> third party patents</font>     and other <font color="blue">intellectual property</font> claims and <font color="blue"><font color="blue">litigation</font> initiated by us</font> to     protect our patents and other <font color="blue">intellectual property</font> rights may be costly for     us and time consuming to our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Such costs may be <font color="blue">prohibitive</font> and     may  affect our ability to <font color="blue">defend against</font> or <font color="blue">initiate patent</font> and other     <font color="blue">intellectual property</font>                                           16     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>claims</td>
    </tr>
    <tr>
      <td>In  addition,  any  <font color="blue">litigation</font> of this type might require our     <font color="blue">management</font> to <font color="blue">focus on matters outside</font> of the day-to-day <font color="blue">operations</font> of our     business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">defend against</font> any type of <font color="blue">intellectual property</font>     claim or protect our own <font color="blue">intellectual property</font> may have a material adverse     effect on our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue">significant</font> <font color="blue">competition</font></font>, and many of our <font color="blue">competitors</font> have greater     financial, marketing and other <font color="blue">resources than</font> we do, <font color="blue">which may affect</font> our     <font color="blue">future success</font></td>
    </tr>
    <tr>
      <td>The medical device market, <font color="blue">particularly</font> in the area of <font color="blue">electrophysiology</font>     products,  is <font color="blue">highly competitive</font> and is <font color="blue">characterized</font> by rapid product     <font color="blue">development</font> and <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have access to     <font color="blue"><font color="blue">significant</font>ly</font> greater financial, marketing and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>The  <font color="blue">greater resources</font> of our <font color="blue">competitors</font> could enable them to develop     <font color="blue">competing products</font> more quickly so as to make it <font color="blue">difficult</font> for us to develop     a share of the market for these products</td>
    </tr>
    <tr>
      <td>By having <font color="blue">greater resources</font>, our     <font color="blue">competitors</font> may also be able to respond more quickly to <font color="blue">technology</font> changes     in the <font color="blue">marketplace may</font> be able to <font color="blue">better market</font> their products and may be     able to obtain <font color="blue">regulatory approval</font> for products more <font color="blue">quickly than</font> we can</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success</font> will depend on our ability to <font color="blue">remain competitive with</font>     other <font color="blue">developers</font> of <font color="blue">medical devices</font> and therapies</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">reimbursement</font> might be denied, might ultimately be at levels     which <font color="blue">effective</font>ly reduce our prices, or might be unavailable for some of our     products, resulting in a reduction in <font color="blue">revenue from</font> the sale of our products</td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">generally purchased by physicians</font> or <font color="blue">medical institutions</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, third-party payors, such as Medicare, Medicaid and     private  insurers,  are billed for the <font color="blue">healthcare services provided</font> to     <font color="blue">patients using</font> those products</td>
    </tr>
    <tr>
      <td>Similar <font color="blue">reimbursement</font> <font color="blue"><font color="blue">arrangement</font>s</font> exist in     several European countries</td>
    </tr>
    <tr>
      <td>Third-party payors are <font color="blue">increasingly challenging</font>     the  prices  charged for <font color="blue">medical products</font> and services and are putting     <font color="blue">pressure on medical equipment suppliers</font> to <font color="blue">reduce prices</font></td>
    </tr>
    <tr>
      <td><font color="blue">Initiatives </font>to     limit the growth of healthcare costs, including price regulation, are also     underway in several countries in which we do business</td>
    </tr>
    <tr>
      <td><font color="blue">Implementation </font>of     healthcare reforms in the <font color="blue"><font color="blue">United States</font> </font>and other <font color="blue">countries may limit</font> the     price of, or the level at which, <font color="blue">reimbursement</font> is provided for our products     and <font color="blue">adversely affect both</font> our <font color="blue">pricing flexibility</font> and the demand for our     products</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">procedures involving</font> the EP-WorkMate^^®^, our EP-3™ Stimulator, our     EP-4™ Stimulator, our integrated RPM™ Navigation <font color="blue">technology</font>, our ALERT^^®^     System <font color="blue">product line</font> and our ViewFlex™ <font color="blue">catheters currently</font> are eligible for     <font color="blue">reimbursement</font> at varying levels, some of <font color="blue">which will</font> need to increase for us     to continue to <font color="blue">increase revenues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Maintaining </font>and increasing levels of     third-party payor <font color="blue">reimbursement</font> <font color="blue">will likely</font> be tied to economic benefits     realized through use of our products and patient outcomes and resulting     market <font color="blue">acceptance</font> of those products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">significant</font>     <font color="blue">economic benefits from</font> the use of our products can or will be realized or     that <font color="blue">patient outcomes from</font> the use of our <font color="blue">products will</font> be <font color="blue"><font color="blue">significant</font>ly</font>     improved</td>
    </tr>
    <tr>
      <td>In addition, changes in FDA <font color="blue">regulations</font> or in third-party payor     policies  could  limit  or  reduce <font color="blue">reimbursement</font> or make <font color="blue">reimbursement</font>     unavailable for <font color="blue">procedures using</font> our products</td>
    </tr>
    <tr>
      <td>In any of those events, or if     third-party <font color="blue">reimbursement</font> does not become available for products we may     develop in the future, our business, results of <font color="blue">operations</font> and financial     <font color="blue">condition could</font> be <font color="blue">materially adversely</font> affected</td>
    </tr>
    <tr>
      <td>The success of our business is <font color="blue"><font color="blue">dependent</font> on</font> our <font color="blue">key personnel</font> and the loss     of  any of these <font color="blue">personnel could</font> have a material adverse effect on our     business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The success of our business is <font color="blue">dependent</font>, to a <font color="blue">significant</font> extent, upon the     <font color="blue">abilities</font> and <font color="blue">continued efforts</font> of our senior <font color="blue">management</font> team, including     David A Jenkins, our President, Chief Executive Officer, Chief Operating     Officer and Chairman of our Board of Directors and C Bryan Byrd, our Vice     President of Engineering and Manufacturing</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success also depends upon</font>     certain of our research and <font color="blue">development</font> and other <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">None     </font>of our other executive officers or key <font color="blue">scientific personnel</font> currently has an     <font color="blue">employment</font> <font color="blue">agreement</font> with us</td>
    </tr>
    <tr>
      <td>We currently maintain key-man life insurance     on  Mr</td>
    </tr>
    <tr>
      <td>Byrd,  but  there can be no assurance that this <font color="blue">policy will</font> be     maintained or renewed</td>
    </tr>
    <tr>
      <td>The loss of any of these persons and the <font color="blue">inability</font> to     <font color="blue">quickly attract replacements</font> for these <font color="blue">key personnel</font> could have a material     adverse  effect  on  our business, results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>We believe our <font color="blue">future success</font> will depend <font color="blue">substantially</font> upon our     ability to attract and retain <font color="blue">highly qualified technical</font> and <font color="blue">management</font>     personnel</td>
    </tr>
    <tr>
      <td>We  believe  that there is and <font color="blue">will continue</font> to be intense     <font color="blue">competition</font> for <font color="blue">qualified personnel</font> in this industry</td>
    </tr>
    <tr>
      <td>We might not be able to attract, manage and retain our <font color="blue">sales force</font> and     third-party <font color="blue">distributor</font>s, <font color="blue">which may affect</font> our ability to promote and sell     our products</td>
    </tr>
    <tr>
      <td>We utilize our own <font color="blue">direct sales</font> and <font color="blue">marketing force</font> to sell and promote our     products in the <font color="blue"><font color="blue">United States</font> </font>and France</td>
    </tr>
    <tr>
      <td>We may not be able to continue to     attract, manage and retain a <font color="blue">qualified sales</font> and <font color="blue">marketing force</font> that can     <font color="blue">successfully</font> promote our products, which <font color="blue">could materially</font> adversely affect     our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">generate sales throughout</font> the rest of the <font color="blue">world through</font> a network of     in<font color="blue">dependent</font> third-party <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>While we do not consider any single     <font color="blue">distributor</font> to be material to our business, we might not be able to replace     existing  <font color="blue">distributor</font>s  on a <font color="blue">timely basis</font>, or do so <font color="blue">on terms which</font> are     <font color="blue">commercially reasonable</font> if <font color="blue">present relationships</font> are terminated</td>
    </tr>
    <tr>
      <td>Further, we     might not be able to make <font color="blue"><font color="blue">arrangement</font>s</font> with new <font color="blue">distributor</font>s to <font color="blue">access new</font>     <font color="blue">international</font>  markets</td>
    </tr>
    <tr>
      <td>If our current or future <font color="blue">distributor</font>s are not     successful in actively and <font color="blue">effective</font>ly marketing our products, it could have     a material                                           17     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>adverse effect on our business and prospects</td>
    </tr>
    <tr>
      <td>In the <font color="blue">fourth quarter</font> of 2005,     we terminated our <font color="blue"><font color="blue">agreement</font>s</font> with our <font color="blue">Armenian and German </font><font color="blue">distributor</font>s and     our <font color="blue">relationship with</font> our European <font color="blue">sales manager</font></td>
    </tr>
    <tr>
      <td><font color="blue">The German </font><font color="blue">distributor</font> is     contesting the <font color="blue">termination</font>, and while we believe its claim is <font color="blue">without merit</font>,     we cannot, at this time, estimate the costs we may incur in enforcing this     <font color="blue">termination</font> or the <font color="blue">impact on</font> our revenue</td>
    </tr>
    <tr>
      <td>Our sales in Europe may have been     impacted in the <font color="blue">fourth quarter</font> of 2005 by the <font color="blue">termination</font> of our <font color="blue">European     </font><font color="blue">sales manager</font> and the <font color="blue">termination</font> of these <font color="blue">distributor</font> relationships</td>
    </tr>
    <tr>
      <td>We     believe this decrease in sales in Europe <font color="blue"><font color="blue">may continue</font> until</font> we are able to     replace our European manager and <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>Our  business  could be subject to <font color="blue">product <font color="blue">liability</font></font> claims, which, if     successful,  could  have a material adverse effect on our business and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We face an inherent business risk of exposure to <font color="blue">product <font color="blue">liability</font></font> and other     claims and lawsuits in the event that our <font color="blue">technologies</font> or products are     alleged to have resulted in <font color="blue">adverse effects</font></td>
    </tr>
    <tr>
      <td>We may not be able to avoid     <font color="blue">significant</font> <font color="blue">liability</font> exposure as our products are <font color="blue">highly complex</font> and some     are or will be used in <font color="blue">relatively</font> new medical procedures and in situations     where there is a <font color="blue">potential risk</font> of serious injury, adverse side effects or     death</td>
    </tr>
    <tr>
      <td>In addition, misuse of these products, including the misuse or reuse     of our catheters, may increase the risk of a patient experiencing adverse     effects and, as a result, the risk of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient <font color="blue">insurance coverage</font></font>, and we may not be able to     obtain <font color="blue">sufficient coverage at</font> a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>We currently maintain     product  <font color="blue">liability</font>  insurance  with  <font color="blue">coverage limits</font> of dlra5cmam000cmam000 per     occurrence and dlra5cmam000cmam000 in the <font color="blue">aggregate per year</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that this coverage is or will be adequate to <font color="blue">cover future</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>insurance is expensive and may not be available to us in the future</td>
    </tr>
    <tr>
      <td>An     <font color="blue">inability</font> to obtain or maintain <font color="blue">product <font color="blue">liability</font></font> insurance at acceptable     costs or to otherwise protect against potential <font color="blue">product <font color="blue">liability</font></font> claims     could  prevent  or inhibit the <font color="blue">commercialization</font> of some or all of our     products</td>
    </tr>
    <tr>
      <td>A successful claim <font color="blue">against us</font> or <font color="blue">settlement by us</font> in excess of our     <font color="blue">insurance coverage</font> or our <font color="blue">inability</font> to maintain insurance, could have a     material adverse effect on our business, results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">risks associated with sales</font> in <font color="blue">multiple countries</font></td>
    </tr>
    <tr>
      <td>We derive a <font color="blue">significant</font> portion of our <font color="blue">revenues from sources outside</font> the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In 2005, 2004, and 2003, approximately 23prca, 22prca, and 41prca,     <font color="blue">respectively</font>, of our net sales were <font color="blue">derived from sales outside</font> the United     States</td>
    </tr>
    <tr>
      <td>We  expect  <font color="blue">international</font>  sales <font color="blue">will continue</font> to represent a     <font color="blue">significant</font> percentage of our <font color="blue">total sales</font></td>
    </tr>
    <tr>
      <td>We sell our products in Europe,     Japan, Turkey, Saudi Arabia and China, <font color="blue">among others</font></td>
    </tr>
    <tr>
      <td>While we attempt to     mitigate risks associated with <font color="blue">international</font> sales, as a result of the     <font color="blue">significant</font> portion of our revenues derived from such <font color="blue">international</font> sales,     we are subject to <font color="blue">associated risks</font>, including:           •   <font color="blue"><font color="blue">United States</font> </font><font color="blue">export license requirements</font> and unauthorized re-export     of our products to non-<font color="blue"><font color="blue">United States</font> </font>approved jurisdictions, non-compliance     with which, or the occurrence of which can result in fines, injunctions,     civil penalties, recall or seizure of products, total or <font color="blue">partial suspension</font>     of foreign sales and criminal prosecution, among other things;           •   <font color="blue">currency devaluations</font> and <font color="blue">fluctuations</font> in <font color="blue">currency exchange rates</font>,     <font color="blue">particularly</font> in Europe in <font color="blue">connection</font> with the euro and pounds sterling;           •   imposition of, or increases in, <font color="blue">customs duties</font> and other tariffs;           •   <font color="blue">inability</font> to <font color="blue">definitively</font> determine or <font color="blue">satisfy legal requirements</font>;           •   <font color="blue">foreign tax laws</font> and <font color="blue">potential increased costs associated with</font>     <font color="blue">overlapping tax structures</font>;           •   <font color="blue">inability</font> to <font color="blue">effective</font>ly enforce contract or <font color="blue">legal rights</font>;           •   <font color="blue">inability</font> to obtain complete financial, end-user and other information     under local legal, judicial, regulatory, disclosure and other systems or     from foreign <font color="blue">distributor</font>s;           •   unexpected changes in <font color="blue">regulatory requirements</font>;           •   <font color="blue">nationalization</font> and other risks, which could result from a change in     <font color="blue">government</font> or other political, social or <font color="blue">economic instability</font>;                                           18     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>  •   <font color="blue">extended collection periods</font> for <font color="blue">accounts receivable</font>;           •   <font color="blue">potentially</font> inadequate <font color="blue">protections</font> of <font color="blue">intellectual property</font> rights;           •   <font color="blue"><font color="blue">restrictions</font> on</font> repatriation of earnings; and           •   the effects of terrorism, wars or other <font color="blue">geopolitical events which</font>,     directly or indirectly, impact the demands for products <font color="blue">manufacture</font>d or sold     by <font color="blue"><font color="blue">United States</font> </font>companies or the <font color="blue">global economy generally</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">risks could</font> have a material adverse effect on our ability to maintain     and <font color="blue">expand foreign sales</font></td>
    </tr>
    <tr>
      <td>Our failure to maintain and <font color="blue">expand foreign sales</font>     would have a material adverse effect on our business, results of <font color="blue">operations</font>     and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">export controls may</font> not be adequate to <font color="blue">ensure <font color="blue">compliance with</font></font> United     States <font color="blue">export laws</font>, especially when we sell our products to <font color="blue">distributor</font>s     over which we have limited control</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">United States</font> </font><font color="blue">government</font> has declared an embargo that restricts the     export of products and services to a number of countries, including Iran,     Syria, Sudan and Cuba, for a variety of reasons, including the <font color="blue">support by</font>     these countries of terrorism</td>
    </tr>
    <tr>
      <td>We sell our products through <font color="blue">distributor</font>s in     Europe, Asia and the Middle East, and in <font color="blue">such circumstances</font>, the <font color="blue">distributor</font>     is responsible for <font color="blue">interacting with</font> the end user of our products, including     to assist in the set up of any <font color="blue">products purchased by such</font> end user</td>
    </tr>
    <tr>
      <td>In order     to <font color="blue">comply with</font> <font color="blue"><font color="blue">United States</font> </font><font color="blue">export laws</font>, we have instituted export controls     including  training  for  our  personnel  in  export  <font color="blue">restrictions</font> and     requirements, appointing an <font color="blue">export control officer</font> to oversee our export     procedures, executing <font color="blue"><font color="blue">agreement</font>s</font> with our <font color="blue">distributor</font>s that include defining     their territory for sale and <font color="blue">requirements pertaining</font> to <font color="blue"><font color="blue">United States</font> </font>export     laws, obtaining end user information from our <font color="blue">distributor</font>s and screening it     to <font color="blue">restricted party lists</font> maintained by the <font color="blue"><font color="blue">United States</font> </font><font color="blue">government</font></td>
    </tr>
    <tr>
      <td><font color="blue">While     </font>we believe that these procedures are adequate to prevent the export or     re-export of our <font color="blue"><font color="blue">products into</font> countries <font color="blue">under <font color="blue">embargo by</font></font></font> the <font color="blue"><font color="blue">United States</font> </font>    <font color="blue">government</font>, we <font color="blue">cannot assure</font> you that our <font color="blue">products will</font> not be exported or     re-exported  by  our  <font color="blue">distributor</font>s  <font color="blue">into such restricted countries</font></td>
    </tr>
    <tr>
      <td>In     particular, our <font color="blue">control over</font> what our <font color="blue">distributor</font>s do with our products is     <font color="blue">necessarily</font> limited, and we <font color="blue">cannot assure</font> you that they will not sell our     products to an end user in a country in violation of <font color="blue"><font color="blue">United States</font> </font>export     laws</td>
    </tr>
    <tr>
      <td>Any violation of <font color="blue"><font color="blue">United States</font> </font>export <font color="blue">regulations</font> could result in     substantial legal, consulting and <font color="blue"><font color="blue">accounting</font> costs</font>, and <font color="blue">significant</font> fines     and/or <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>In the event that our products are exported to     countries under a <font color="blue"><font color="blue">United States</font> </font><font color="blue">trade embargo</font> in violation of applicable     United  States <font color="blue">export laws</font> and <font color="blue">regulations</font>, such violations, costs and     penalties or other actions that could be taken <font color="blue">against us</font> could adversely     affect  our  reputation and/or have an adverse effect on our business,     <font color="blue">financial condition</font>, prospects or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have sold and <font color="blue">may continue</font> to sell, with a license, our <font color="blue">products into</font>     countries that are <font color="blue">under <font color="blue">embargo by</font></font> the <font color="blue"><font color="blue">United States</font> </font>and as a result have     incurred  and  <font color="blue">may continue</font> to incur <font color="blue">significant</font> legal, consulting and     <font color="blue">accounting</font> fees and may place our Company’s <font color="blue">reputation at risk</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">United States</font> </font><font color="blue">export laws</font> permit the sale of <font color="blue">medical products</font> to certain     countries <font color="blue">under <font color="blue">embargo by</font></font> the <font color="blue"><font color="blue">United States</font> </font><font color="blue">government</font> if the seller of     <font color="blue">such products</font> obtains a license to do so, <font color="blue">which requirements</font> are in place     because the <font color="blue"><font color="blue">United States</font> </font>has <font color="blue">designated such countries as</font> state sponsors of     terrorism</td>
    </tr>
    <tr>
      <td>Certain of our products have been sold in Syria <font color="blue">under license</font>     through  a  distribution <font color="blue">agreement</font> with an in<font color="blue">dependent</font> <font color="blue">distributor</font></td>
    </tr>
    <tr>
      <td>In     addition, certain of our products were <font color="blue">distributed</font> in Iran without United     States <font color="blue">government</font>al <font color="blue">authorization</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">aggregate revenue generated by sales</font>     of our <font color="blue">products into</font> <font color="blue">Syria and Iran </font>have <font color="blue">been immaterial</font> to our business and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may continue</font> to supply <font color="blue">medical devices</font> to Syria and other countries that     are  under  <font color="blue">embargo by</font> the <font color="blue"><font color="blue">United States</font> </font><font color="blue">government</font> upon obtaining all     <font color="blue">necessary</font> licenses</td>
    </tr>
    <tr>
      <td>We do not believe, however, that our <font color="blue">sales into such</font>     <font color="blue">countries will</font> be material to our business or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>are risks we face in selling to countries under <font color="blue"><font color="blue">United States</font> </font>embargo,     including, but not limited to, <font color="blue">possible damage</font> to our reputation for sales     to countries that are deemed to <font color="blue">support terrorism</font>, and failure of our export     controls to <font color="blue">limit sales strictly</font> to the terms of the relevant license, which     <font color="blue">failure may</font> result in civil and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>In addition, we may     incur  <font color="blue">significant</font>  legal, consulting and <font color="blue"><font color="blue">accounting</font> costs</font> in ensuring     <font color="blue">compliance with</font> our <font color="blue">export licenses</font> to <font color="blue">countries under embargo</font></td>
    </tr>
    <tr>
      <td>Any damage to our reputation from such sales, failure to <font color="blue">comply with</font> the     terms of our <font color="blue">export licenses</font> or the <font color="blue">additional</font> costs we incur in making such     sales  could have a material adverse <font color="blue">impact on</font> our business, financial     condition, prospects or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>Sales of our <font color="blue">products into</font> Iran are <font color="blue">under <font color="blue">investigation</font> by</font> the <font color="blue"><font color="blue">United States</font> </font>    Department of Commerce, and we <font color="blue">cannot assure</font> you that such <font color="blue">investigation</font>     will not result in <font color="blue">significant</font> fines or penalties that could have a material     adverse effect on the Company’s business, <font color="blue">financial condition</font>, prospects, or     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">United States</font> </font>Department of Commerce has <font color="blue">requested certain</font> information     relating to, and is conducting an <font color="blue">investigation</font> into, certain sales of our     <font color="blue">products into</font> Iran</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Commission </font>is conducting an informal     inquiry  to  determine  whether  there have <font color="blue">been violations</font> of certain     provisions of the <font color="blue">federal securities laws</font> in <font color="blue">connection</font> with the Company’s     financial and <font color="blue">accounting</font> reporting, including relating to <font color="blue">disclosures</font> the     Company made in its Form 8-K filed with the <font color="blue">Commission </font>on August 12, 2005     regarding the ongoing <font color="blue">government</font> <font color="blue">investigation</font> of sales by the Company of     its <font color="blue">products into</font> Iran</td>
    </tr>
    <tr>
      <td>We are <font color="blue">cooperating fully with</font> the federal <font color="blue">government</font>     in <font color="blue">connection</font> with these matters</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue"><font color="blue">United States</font> </font>Department     of Justice, through the <font color="blue"><font color="blue">United States</font> </font>Attorney’s Office for the District of     New Jersey, had also <font color="blue">requested certain</font> information and had initiated an     <font color="blue">investigation</font> into the sales of our <font color="blue">products into</font> Iran</td>
    </tr>
    <tr>
      <td>In March 2006, the     <font color="blue"><font color="blue">United States</font> </font>Attorney’s Office for the District of <font color="blue">New Jersey </font>informed the     Company that it will not prosecute the Company in <font color="blue">connection</font> with this     matter</td>
    </tr>
    <tr>
      <td>Based on the Company’s <font color="blue">investigation</font> of these matters to date, <font color="blue">management</font>     believes that a limited number of the Company’s <font color="blue">heart monitor systems</font> were     <font color="blue">distributed</font> to <font color="blue">medical facilities</font> in Iran without <font color="blue"><font color="blue">United States</font> </font><font color="blue">government</font>al     <font color="blue">authorization</font></td>
    </tr>
    <tr>
      <td>We  believe  the <font color="blue">aggregate revenues generated by</font> these     <font color="blue">transactions</font> were not material to the Company’s <font color="blue">cumulative financial</font> results     during the period in which the <font color="blue">transactions</font> occurred</td>
    </tr>
    <tr>
      <td>At this time, we do     not have a license to <font color="blue">sell products</font> in Iran and have not entered into any     <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">distributor</font>s to distribute our products in Iran</td>
    </tr>
    <tr>
      <td>We have     incurred legal, consulting and <font color="blue">accounting</font> expenses associated with the     <font color="blue">investigation</font>s by the <font color="blue"><font color="blue">United States</font> </font>Department of Justice, Department of     Commerce and the Commission, amounting to dlra911cmam000 in the <font color="blue">third quarter</font> of     2005 and dlra519cmam000 in the <font color="blue">fourth quarter</font> of 2005</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that     the ongoing <font color="blue">investigation</font>s by the Department of Commerce and the <font color="blue">Commission </font>    will not result in <font color="blue">significant</font> costs, fines or penalties that could have a     material adverse effect on our business, <font color="blue">financial condition</font>, prospects, or</td>
    </tr>
  </tbody>
</table>